cholesterol

Benzinga recently had the opportunity to pick the brain of Dicerna Pharmaceuticals Inc (NASDAQ: DRNA) CEO Douglas M. Fambrough, Ph.D. We first looked into what RNA interference is and how it's used to treat genetic diseases. We then talked products, partnerships and stock performance and...

Benzinga recently had the chance to chat with Dicerna Pharmaceuticals Inc (NASDAQ: DRNA)’s CEO Douglas M. Fambrough, Ph.D., who explained what RNA interference is and how it is used to treat genetic diseases. Beyond this theoretical explanation, the exec walked us through the company’s...

Benzinga recently had the chance to chat with Dicerna Pharmaceuticals Inc (NASDAQ: DRNA)’s CEO Douglas M. Fambrough, Ph.D., who explained what RNA interference (RNAI) is and how it is used to treat genetic diseases. Beyond this theoretical explanation, the exec elaborated on the company...

Ever heard of RNA Interference? In case you haven’t, Benzinga reached out to Dicerna Pharmaceuticals Inc (NASDAQ: DRNA)’s CEO Douglas M. Fambrough, Ph.D., and asked him to explain how it works. Silencing Genes “RNA Interference (RNAI) is a natural process. It is a biological...

Gbola Amusa, Chardan Capital Markets' head of healthcare research, commented in a note on Monday that investors should be "more selective" in the biotech space. As such, the analyst downgraded shares of Regeneron Pharmaceuticals Inc (NASDAQ: REGN) to Neutral from Buy with an unchanged $565 price...

The plot deepens regarding the biotech company Amarin (NASDAQ: AMRN) and its controversial cholesterol-controlling drug, Vascepa. As previously reported on Benzinga, Amarin was waiting to hear the results of a Food and Drug Administration ruling. The company had appealed the FDA's October...